UBS Group
ENGNW icon

UBS Group’s enGene Therapeutics Warrants ENGNW Stock Holding History

UBS Group’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,706
Closed -$4.76K – 10669
2025
Q3 		$4.76K Sell
6,706
-12,958
-66% -$9.82K ﹤0.01% 8926
2025
Q2 		$16.1K Sell
19,664
-2,269
-10% -$1.58K ﹤0.01% 8581
2025
Q1 		$13.2K Buy
21,933
+19,106
+676% +$15.7K ﹤0.01% 8470
2024
Q4 		$2.38K Sell
2,827
-381
-12% -$562 ﹤0.01% 9055
2024
Q3 		$2.76K Sell
3,208
-8,952
-74% -$10.6K ﹤0.01% 8372
2024
Q2 		$14.5K Buy
+12,160
New +$38.9K ﹤0.01% 7512

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $2.1B AUM 70.99% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $25.9B AUM 21.78% 1-Year Est. Return
SCM
Saba Capital Management New York $3.12B AUM 13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $10.9B AUM 60.68% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return